Low-Dose Ketamine for Complex Regional Pain Syndrome (CRPS)

What Is Complex Regional Pain Syndrome?

Complex regional pain syndrome (CRPS) is a debilitating chronic pain condition that typically develops after an injury, surgery, or vascular event — often affecting a single limb. It is characterized by pain that is disproportionate to the initial injury in both severity and duration, accompanied by sensory, vasomotor, sudomotor, motor, and trophic changes. CRPS is classified into two subtypes:

• CRPS Type I (formerly reflex sympathetic dystrophy): Occurs without a confirmed nerve injury. Accounts for approximately 90% of cases.
• CRPS Type II (formerly causalgia): Occurs following a documented peripheral nerve injury.

Despite advances in understanding, CRPS remains one of the most treatment-resistant pain conditions. Conventional therapies — physical therapy, sympathetic nerve blocks, anticonvulsants, opioids, and bisphosphonates — provide incomplete relief for many patients. Low-dose ketamine has emerged as one of the most promising interventions for CRPS, supported by a growing body of clinical evidence demonstrating both acute and sustained analgesic benefit.

CRPS Pathophysiology and Why Ketamine Works

Central Sensitization

The hallmark of CRPS is central sensitization — a state of hyperexcitability in the spinal cord and brain that amplifies pain signals far beyond what peripheral tissue damage would warrant. Central sensitization depends heavily on NMDA receptor activation in dorsal horn neurons. Glutamate binding to NMDA receptors triggers sustained calcium influx, activating intracellular kinases that phosphorylate ion channels and receptors, lowering the threshold for neuronal firing.

Ketamine is the most potent clinically available NMDA receptor antagonist used at sub-anesthetic doses. By blocking NMDA receptors, ketamine directly interrupts the molecular machinery of central sensitization — the core mechanism driving CRPS pain. This is fundamentally different from opioids and most other analgesics, which modulate pain signaling without addressing the underlying sensitization.

Neuroinflammation

CRPS involves robust neuroinflammatory processes at both peripheral and central levels. Activated microglia and astrocytes in the spinal cord release pro-inflammatory cytokines (TNF-alpha, IL-1beta, IL-6) that maintain and amplify central sensitization. Peripheral inflammation in the affected limb produces neuropeptide release (substance P, CGRP) that further drives pain and trophic changes.

Ketamine's anti-inflammatory properties contribute to its efficacy in CRPS through:

• Inhibition of nuclear factor kappa-B (NF-kappaB) signaling
• Reduction of pro-inflammatory cytokine production
• Suppression of microglial activation
• Modulation of toll-like receptor 4 (TLR4) signaling

Maladaptive Neuroplasticity

Functional neuroimaging reveals significant cortical reorganization in CRPS patients, similar to phantom limb pain. The somatosensory representation of the affected limb shrinks, and there is altered connectivity between motor, sensory, and emotional brain regions. Ketamine promotes adaptive neuroplasticity through BDNF-mediated synaptogenesis, potentially reversing some of the maladaptive cortical changes that perpetuate CRPS.

Sympathetic Nervous System Dysregulation

CRPS involves autonomic dysfunction manifested as temperature asymmetry, color changes, and sweating abnormalities in the affected limb. While ketamine does not directly target sympathetic neurons, its central effects on pain processing and its modulation of the default mode network and stress-response circuits may indirectly normalize autonomic function as pain is reduced.

Clinical Evidence

Intravenous Infusion Trials

Sigtermans et al. (2009) — This landmark randomized, double-blind, placebo-controlled trial enrolled 60 patients with CRPS-1 and administered either ketamine (titrated to maximum plasma levels of 300 ng/mL, approximately 0.35 mg/kg/h) or placebo infusions over 4.2 days. The ketamine group showed significant pain reduction during treatment (mean NRS reduction of 2.68 points), and this benefit persisted for at least 11 weeks after the infusion series. This trial provided the strongest evidence to date for ketamine in CRPS.

Schwartzman et al. (2009) — A randomized, placebo-controlled trial of 19 CRPS patients receiving IV ketamine (25 mg/h escalating over 4 hours daily for 10 days) demonstrated significant improvements in pain intensity, movement-related pain, and thermal sensitivity at 12-week follow-up.

Kiefer et al. (2008) — An open-label study using anesthetic-dose ketamine (initiated at sub-anesthetic levels and titrated to anesthetic doses over 5 days) in 20 patients with refractory CRPS-1 reported complete remission in all patients. While this involved higher doses than typical low-dose protocols, it demonstrated ketamine's capacity to "reset" central sensitization in CRPS.

Prolonged Low-Dose Infusions

Some centers have adopted prolonged sub-anesthetic infusion protocols for CRPS:

• Dose: 0.1-0.35 mg/kg/h continuous IV infusion
• Duration: 4-14 days inpatient
• Monitoring: Continuous cardiac monitoring, hepatic panels, psychiatric assessment
• Results: Multiple case series report 50-80% pain reduction with benefits lasting weeks to months

Sublingual and Oral Maintenance

Following initial IV response, sublingual and oral protocols can extend benefit:

• Sublingual troches: 25-100 mg, two to three times daily
• Oral solution: 10-50 mg, three to four times daily (lower bioavailability requires dose adjustment)
• Purpose: Maintenance therapy between IV booster sessions or as standalone long-term management
• Evidence: Case series and clinical experience support this approach, though controlled trials specific to CRPS maintenance are lacking

Treatment Protocols for CRPS

Initial Assessment

Before initiating ketamine for CRPS, comprehensive assessment should include:

• Confirmation of CRPS diagnosis using the Budapest criteria
• Pain severity scoring (NRS, Brief Pain Inventory)
• Functional assessment (grip strength, range of motion, walking distance)
• Psychological screening for comorbid depression, anxiety, and PTSD
• Medical screening for contraindications
• Baseline labs including hepatic function, renal function, and CBC
• Current medication review, with attention to drug interactions

Acute IV Infusion Series

Standard outpatient protocol:

• 0.5 mg/kg IV over 40 minutes, 2-3 times per week for 2-3 weeks
• Cardiovascular monitoring during and for 30-60 minutes after each infusion
• Pain assessment before, during, and after each infusion
• Response evaluation after 4-6 infusions to determine continuation

Extended inpatient protocol (for severe or refractory CRPS):

• Day 1: 0.1 mg/kg/h continuous IV infusion
• Days 2-3: Titrate to 0.2-0.3 mg/kg/h based on response and tolerability
• Days 4-7 (or longer): Maintain at effective rate, maximum 0.35 mg/kg/h
• Daily monitoring: Vitals, pain scores, liver function, cognitive assessment, nausea management

Transition to Maintenance

Patients who respond to IV infusion series can transition to:

1. Periodic IV boosters: Monthly or quarterly infusions based on symptom recurrence
2. Sublingual troches: Daily or as-needed dosing for ongoing NMDA antagonism
3. Combination approach: Regular sublingual dosing with intermittent IV boosters for flares

Dosing Adjustments for CRPS

CRPS patients often require higher ketamine doses than depression patients due to the intensity of central sensitization:

• Sub-anesthetic infusion rates for CRPS may reach 0.35 mg/kg/h (versus 0.5 mg/kg over 40 minutes for depression)
• Sublingual maintenance doses may range from 50-150 mg per session (versus 25-75 mg for depression)
• Weight-based dosing should account for the prolonged infusion durations used in CRPS
• Tolerance management is particularly important given the potentially longer treatment courses

Multimodal Treatment Integration

Ketamine produces the best CRPS outcomes when integrated into a comprehensive multimodal treatment plan:

Physical and Occupational Therapy

Functional rehabilitation is essential for CRPS recovery. Ketamine's analgesic effects can facilitate:

• Graded motor imagery programs
• Progressive loading and desensitization
• Active range of motion exercises that would otherwise be limited by pain
• Timing therapy sessions to coincide with peak ketamine analgesia can maximize functional gains

Psychological Interventions

CRPS is associated with significant psychological distress, fear-avoidance behavior, and catastrophizing — all of which amplify pain through central mechanisms. Ketamine's rapid antidepressant effects may improve engagement with:

• Cognitive behavioral therapy for chronic pain
• Acceptance and commitment therapy
• Pain neuroscience education
• Integration therapy targeting pain-related beliefs and behaviors

Interventional Procedures

Ketamine can complement other interventional approaches:

• Sympathetic nerve blocks: May provide additive benefit when combined with ketamine
• Spinal cord stimulation: Ketamine can help with pain management during trial periods and device optimization
• Regional anesthesia: Peripheral nerve catheters combined with systemic ketamine target both peripheral and central pain mechanisms

Pharmacological Adjuncts

Combination therapy may enhance ketamine's CRPS efficacy:

• Gabapentinoids (gabapentin, pregabalin): Complementary mechanisms at calcium channels
• Lidocaine infusions: Additional sodium channel blockade
• Bisphosphonates: May address bone metabolism abnormalities in early CRPS
• Low-dose naltrexone: Potential synergy through microglial modulation

Safety Considerations Specific to CRPS

Prolonged Treatment Courses

CRPS often requires longer ketamine treatment courses than depression, increasing cumulative exposure. Long-term safety monitoring should include:

• Serial liver function tests (baseline, then every 1-3 months during active treatment)
• Bladder safety assessments (urinary symptom questionnaire, urinalysis)
• Cognitive assessments at baseline and periodically
• Abuse potential screening, particularly in patients with chronic pain who may be at higher risk for substance use

Managing Side Effects

Common side effects during CRPS-focused ketamine infusions:

• Nausea: Prophylactic ondansetron 4 mg IV/PO before infusion
• Dissociation: Generally mild at sub-anesthetic doses; benzodiazepine rescue rarely needed
• Hypertension: Blood pressure monitoring; clonidine 0.1 mg PO for sustained elevations
• Vivid dreams or hallucinations: More common with prolonged infusions; low-dose midazolam if distressing

Opioid Interactions

Many CRPS patients are on chronic opioid therapy. Ketamine's opioid system interactions can be leveraged to reduce opioid requirements, but dose adjustments should be made gradually to avoid withdrawal. Coordinated management between the ketamine provider and the patient's pain management team is essential.

Prognosis and Expectations

Patients should be counseled on realistic expectations:

• Ketamine is not a cure for CRPS but can produce clinically meaningful pain reduction
• Response rates in CRPS trials range from 50-75%, typically defined as 30% or greater pain reduction
• Benefits may require multiple treatment sessions or courses before full effect is realized
• Maintenance therapy is often necessary, as CRPS tends to recur when treatment is discontinued
• Best outcomes occur when ketamine is part of a comprehensive rehabilitation approach rather than a standalone therapy
• Some patients achieve sufficient pain relief to significantly improve function and quality of life, even when complete pain elimination is not achieved

References

• Sigtermans MJ, et al. (2009). "Ketamine produces effective and long-term pain relief in patients with complex regional pain syndrome type 1." Pain — Landmark RCT for ketamine in CRPS
• Schwartzman RJ, et al. (2009). "Outpatient intravenous ketamine for the treatment of complex regional pain syndrome." Clinical Journal of Pain — Outpatient IV ketamine protocol for CRPS
• Harden RN, et al. (2010). "Validation of proposed diagnostic criteria (the 'Budapest Criteria') for CRPS." Pain — Diagnostic criteria referenced in clinical assessment
• National Institute of Neurological Disorders and Stroke (NINDS) — Complex Regional Pain Syndrome — NIH overview of CRPS pathophysiology and treatment
• Connolly SB, et al. (2015). "Intravenous ketamine for treatment of chronic pain: a systematic review and meta-analysis." Canadian Journal of Anaesthesia — Meta-analysis including CRPS-focused ketamine studies
• Mayo Clinic — Complex Regional Pain Syndrome — Clinical overview for patients and providers